Could tofacitinib, The first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, Be the breakthrough drug for RA?

Seung Ki Kwok

doi:10.3904/kjim.2014.29.5.577

Could tofacitinib, The first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, Be the breakthrough drug for RA?

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	577-579
Number of pages	3
Journal	Korean Journal of Internal Medicine
Volume	29
Issue number	5
DOIs	https://doi.org/10.3904/kjim.2014.29.5.577
State	Published - 1 Sep 2014

Access to Document

10.3904/kjim.2014.29.5.577

Cite this

@article{627d2eaea2754f1fa375d3417c754eaf,

title = "Could tofacitinib, The first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, Be the breakthrough drug for RA?",

author = "Kwok, \{Seung Ki\}",

year = "2014",

month = sep,

day = "1",

doi = "10.3904/kjim.2014.29.5.577",

language = "English",

volume = "29",

pages = "577--579",

journal = "Korean Journal of Internal Medicine",

issn = "1226-3303",